---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-029401"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2026-01-29T23:59:59+00:00"
generated_at: "2026-05-16T06:15:18.416787+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioMarin prices $850M 5.500% notes due 2034 and syndicates $2B term loan for Amicus acquisition

## Summary
- $850M 5.500% senior notes due 2034; price 100%; expected close Feb 12, 2026.
- Syndicated $2B term loan B, plus $800M term loan A and $600M revolver for pending Amicus acquisition.
- Proceeds from notes and term loans, plus cash on hand, to fund Amicus acquisition consideration and fees.
- If acquisition not completed by Dec 19, 2026, notes subject to special mandatory redemption at 100% plus accrued interest.
- Notes guaranteed by BioMarin subsidiaries including Amicus post-closing; covenants limit debt, dividends, liens.

## SEC filing metadata
- accession: 0001193125-26-029401
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2026-01-29T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000119312526029401/0001193125-26-029401-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000119312526029401/d170996d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-029401
- JSON: https://secwatch.observer/filing/0001193125-26-029401.json
- Plain text: https://secwatch.observer/filing/0001193125-26-029401.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.